Product to be launched immediately
Strides Arcolab has received approval from the United States Food & Drug Administration (USFDA) for Lamivudine and Zidovudine tablets USP, 150 mg/300 mg.
According to IMS data, the US market for Lamivudine and Zidovudine Tablets is approximately $120 million. The product will be manufactured at the company’s oral dosage facility at Bangalore and marketed by Strides in the US Market. The product will be launched in the markets immediately.
Comments are closed.